Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Dermatology Drugs Market by Type (Cosmetic Dermatology, Cutaneous Lymphoma, Other Types), Route of Administration, Indication, Distribution Channel, End User, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030
... The global dermatology drugs market size was valued at $33.39 billion in 2024 and is projected to reach $62.45 billion by 2030, growing at a CAGR of 11.0% during the forecast period. Dermatology Drugs Market ... Read More
-
Metabolic Disorder Therapeutics
... by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Diabetes Therapeutics, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$91.9 Billion by ... Read More
-
Vaginitis Therapeutics
... at a CAGR of 7.5% over the analysis period 2023-2030. Anti-Bacterial, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.7 Billion by the end of the ... Read More
-
Label-free Array Systems
... by 2030, growing at a CAGR of 5.5% over the analysis period 2023-2030. Surface Plasmon Resonance (SPR) Technology, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach ... Read More
-
Glaucoma Therapeutics
... at a CAGR of 3.5% over the analysis period 2023-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$2.9 Billion by the end of ... Read More
-
Hereditary Angioedema
... at a CAGR of 7.7% over the analysis period 2023-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.5 Billion by the end ... Read More
-
Chronic Myelogenous Leukemia Treatment
... reach US$10.1 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and ... Read More
-
Gastroesophageal Reflux Disease (GERD) Therapeutics
... is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2023-2030. Antacids, one of the segments analyzed in the report, is expected to record a 4.4% CAGR ... Read More
-
Global Musculoskeletal System Disorder Market Research Report 2024
... of 4.19% during the forecast period 2024-2030. North American market for Musculoskeletal System Disorder is estimated to increase from $ 77023 million in 2023 to reach $ 100034 million by 2030, at a CAGR of ... Read More
-
Pre-Eclampsia - Pipeline Insight, 2024
... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Pre-Eclampsia: Understanding ... Read More
-
Schizophrenia - Pipeline Insight, 2024
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Schizophrenia: Understanding Schizophrenia: ... Read More
-
Pemphigus Vulgaris (PV) - Market Insight, Epidemiology And Market Forecast - 2034
... ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in the 7MM. In 2023, the market size of metabolic dysfunction-associated steatohepatitis (MASH) was highest in the US ... Read More
-
Neglected Tropical Diseases Diagnosis
... reach US$10.3 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Conventional Method, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach ... Read More
-
Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
... released a research report titled “Global Epilepsy Therapeutics Market (2024 Edition)” which provides an analysis of the Global Epilepsy Therapeutics industry in terms of market segmentation By Generation (First Generation, Second Generation, Third Generation), By ... Read More
-
Myeloproliferative Disorders Drugs
... by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Ph+ Chronic myelogenous leukemia (CML) Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... reach US$4.1 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach ... Read More
-
Focal Segmental Glomerulosclerosis
... by 2030, growing at a CAGR of 6.6% over the analysis period 2023-2030. Primary Disease Type, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$17.9 Billion ... Read More
-
Desmopressin
... of 5.5% over the analysis period 2023-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$866.1 Million by the end of the analysis period. ... Read More
-
Acute Repetitive Seizures
... by 2030, growing at a CAGR of 44.7% over the analysis period 2023-2030. Diastat Rectal Gel, one of the segments analyzed in the report, is expected to record a 46.2% CAGR and reach US$8.4 Billion ... Read More
-
Amyloidosis Treatment
... at a CAGR of 6.6% over the analysis period 2023-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Neuroprotection Therapeutics
... at a CAGR of 6.9% over the analysis period 2023-2030. Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$45.7 Billion by ... Read More
-
Sarcoma Drugs
... at a CAGR of 7.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Type 2 Diabetes - Pipeline Insight, 2024
... pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. ... Read More
-
Cutaneous T-cell lymphoma - Pipeline Insight, 2024
... drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography ... Read More
-
Lou Gehrig’s disease - Pipeline Insight, 2024
... pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. ... Read More
Research Assistance
